Exacis Biotherapeutics
Dr. Rohde has extensive experience developing mRNA technologies and technologies for high-throughput and high-content screening. His work is described in numerous peer-reviewed publications, and has been covered by Technology Review, Nature, Bioscience Magazine, Analytical Chemistry, The Economist, and many others. Dr. Rohde is currently leading Factor’s efforts to apply our RiboSlice™ gene-editing technology, and FactorStem™ cell-reprogramming and differentiation technologies to the development of new research models, including high-throughput screening-compatible human cell libraries, for the study and treatment of Alzheimer’s disease.
This person is not in the org chart
This person is not in any offices
Exacis Biotherapeutics
Exacis Biotherapeutics is a development stage immuno-oncology company harnessing the immune system to cure cancer.